Thursday, September 28, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Chief of Leukemia and Benign Hematology Services
Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Associate Professor, Department of Medicine
Division of Hematology-Oncology
Perelman School of Medicine at the University of Pennsylvania
Attending Physician, Leukemia Program
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Clinical Pharmacist Specialist, Hematology
Clinical Team Leader, Hematology/Oncology Pharmacy
University of Michigan
Ann Arbor, Michigan
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.75 ABIM MOC points
Nurses - 0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)
Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)
IPCE - 0.75 Interprofessional Continuing Education (IPCE) credit
This activity is intended for community-based hematologists/oncologists, nurses, nurse practitioners, physician assistants, and pharmacists involved in the treatment of patients with AML.
The goal of this activity is for the AML care team to be better able to manage patients with FLT3-mutated AML, including diagnosis, prognosis, and treatment.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Chief of Leukemia and Benign Hematology Services
Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Associate Professor, Department of Medicine
Division of Hematology-Oncology
Perelman School of Medicine at the University of Pennsylvania
Attending Physician, Leukemia Program
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Clinical Pharmacist Specialist, Hematology
Clinical Team Leader, Hematology/Oncology Pharmacy
University of Michigan
Ann Arbor, Michigan
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.75
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) (Universal Activity Number: JA0007105-0000-23-010-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 1/30/2023
Valid for credit through: 1/30/2024, 11:59 PM EST
processing....
The goal of this activity is for the AML care team to be better able to manage patients with FLT3-mutated AML, including diagnosis, prognosis, and treatment.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
